Drugs / GS-4321
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT07096193 | Jul 2025 → Jan 2030 expected | hepatitis D virus infection | Gilead Sciences | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GS-4321 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07096193 ↗ |
| Route | Intravenous | “Administered subcutaneous (SC) or intravenously IV” NCT07096193 ↗ |
| Route | Subcutaneous | “Administered subcutaneous (SC) or intravenously IV” NCT07096193 ↗ |